Form 4: Maravai LifeSciences CFO Acquires Shares Through Employee Stock Purchase Plan

Maravai LifeSciences' Chief Financial Officer, Kevin Herde, acquired 1,906 shares of Class A Common Stock through the company's Employee Stock Purchase Plan.

Summary

• Kevin Herde, the Chief Financial Officer of Maravai LifeSciences Holdings, Inc., acquired 1,906 shares of Class A Common Stock.
• The shares were acquired on October 31, 2024, at a price of $5.7 per share.
• This transaction was made through the company's 2020 Employee Stock Purchase Plan.
• The acquisition is exempt under Rule 16b-3 of the Securities Exchange Act of 1934.
• Following the transaction, Mr. Herde directly owns 336,600 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a positive but not overly significant sentiment. The CFO's participation in the stock purchase plan suggests confidence in the company.

Positives

• The acquisition of shares by the CFO demonstrates confidence in the company's future.
• The use of the Employee Stock Purchase Plan indicates a commitment to employee ownership.

Industry Context

This is a routine transaction for a company with an employee stock purchase plan. It is common for executives to participate in such plans.

Comparison to Industry Standards

• Employee stock purchase plans are a common practice among publicly traded companies, particularly in the technology and biotechnology sectors.
• Many companies offer similar plans to align employee interests with shareholder value, such as those offered by companies like Illumina and Thermo Fisher Scientific.
• The specific terms of the plan, such as the discount offered and the purchase price, are typical for such programs.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates management's confidence in the company.
• Employees participating in the stock purchase plan benefit from the opportunity to acquire company shares.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Kevin Herde, CFO, Employee Stock Purchase Plan, Class A Common Stock, SEC Form 4, Insider Trading